%0 Journal Article
%A Ramos-Rincon, Jose-Manuel
%A López-Carmona, María-Dolores
%A Cobos-Palacios, Lidia
%A López-Sampalo, Almudena
%A Rubio-Rivas, Manuel
%A Martín-Escalante, María-Dolores
%A de-Cossio-Tejido, Santiago
%A Taboada-Martínez, María-Luisa
%A Muiño-Miguez, Antonio
%A Areses-Manrique, Maria
%A Martinez-Cilleros, Carmen
%A Tuñón-de-Almeida, Carlota
%A Abella-Vázquez, Lucy
%A Martínez-Gonzalez, Angel-Luís
%A Díez-García, Luis-Felipe
%A Ripper, Carlos-Jorge
%A Asensi, Victor
%A Martinez-Pascual, Angeles
%A Guisado-Vasco, Pablo
%A Lumbreras-Bermejo, Carlos
%A Gómez-Huelgas, Ricardo
%A On Behalf Of The Semi-Covid-Network,
%T Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.
%D 2022
%@ 2077-0383
%U http://hdl.handle.net/10668/21309
%X (1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p
%K COVID-19
%K SARS-CoV-2
%K Spain
%K age ≥ 80
%K mortality
%K remdesivir
%~